SPTX Stock — Seaport Therapeutics, Inc.

Seaport Therapeutics, Inc. (SPTX)

Updated October 16, 2026.

SPTX is a Stock. Total return is 178200.0% over the past 0.6 years, 178183.0 points ahead of SPY at 17.0%.

Seaport Therapeutics is a clinical-stage company developing oral medicines for depression, anxiety, and related neuropsychiatric disorders using its proprietary Glyph platform technology. The company's pipeline includes GlyphAllo, an oral prodrug of allopregnanolone for postpartum depression, and GlyphAgo, an oral prodrug of agomelatine for anxiety and depression. As an early-stage therapeutic company with no approved products, it does not currently distribute dividends and is oriented toward investors with risk tolerance for clinical development timelines and regulatory milestones rather than income generation.

SPTX performance versus SPY

Price and return data through 2026-10-16.

Total return is 178200.0% over the past 0.6 years, 178183.0 points ahead of SPY at 17.0%.

SPTX key facts

Asset type

Stock

Asset class

Equity

Inception date

03/23/2026

Distribution frequency

None

Last close

$17.83 (as of 2026-10-16)

Market cap

$954,449,706

Average volume

184538.0

Payout ratio

0.0%

EPS

$-5.81

How Dividend Vision calculates yield and returns

Distribution rate (the posted rate) uses calculation basis unavailable. Issuer rates can use a different denominator and date, including ex-date NAV. Trailing-12-month yield is the sum of split-adjusted cash distributions with ex-dates in the last 12 months, divided by the published price. It lags a recent raise or cut. Total return uses split-adjusted close with distributions reinvested on the ex-dividend date (a modeling convention, not the cash-settlement date) from the first stored bar on or after inception through the latest bar, compared with the same window on the benchmark. That is the security's total return, not your personal gain/loss.

Yield and safety methodology · Distribution rate methodology · Distribution Safety Score methodology

Sources and review

Primary sources: prices and distributions from Dividend Vision, derived from vendor EOD data.

Reviewed by Bert Sweet, CEO and Co-owner of Dividend Vision. Methodology: Distribution Safety Score.

Who may consider SPTX — and who may not

It is a weaker fit for investors who need monthly cash flow (SPTX does not currently distribute). This is educational context, not a recommendation to buy or sell.

More on SPTX

• All tickers starting with S

Tagged: Healthcare.

Frequently asked questions